POPULARITY
3 episodes with onclive
2 episodes with onclive
2 episodes with onclive
2 episodes with onclive
2 episodes with onclive
2 episodes with onclive
2 episodes with onclive
In today's episode, OncLive teamed up with CURE to present a discussion with David A. Braun, MD, PhD, about his research on determinants of response to immune checkpoint inhibition (ICI) in patients with renal cell carcinoma (RCC). Dr Braun is an assistant professor of medicine (medical oncology), the Louis Goodman and Alfred Gilman Yale Scholar, and a member of the Center of Molecular and Cellular Oncology at Yale Cancer Center in New Haven, Connecticut. In this exclusive interview, Dr Braun discussed the rationale for investigating molecular factors that contribute to exceptional ICI responses among patients with RCC, as well as the key findings from this study. He also shared how these findings may affect cancer care and influence shared decision-making strategies for patients receiving immunotherapy.
In this episode of Oncology Unplugged, a podcast series from OncLive and MedNews Week, podcast host Chandler Park, MD, a medical oncologist at Norton Cancer Institute in Louisville, Kentucky, was joined by Petros Grivas, MD, PhD; and Ruben Raychaudhuri, MD, to talk about a pilot trial investigating neoadjuvant accelerated methotrexate, vinblastine,doxorubicin, and cisplatin (aMVAC) plus pembrolizumab (Keytruda) in patients with non-urothelial muscle-invasive bladder cancer, findings from which were presented at the 2025 Genitourinary Cancers Symposium. Dr Grivas is clinical director of the Genitourinary Cancers Program and a professor in the Clinical Research Division at Fred Hutchinson Cancer Center, as well as a professor in the Division of Hematology and Oncology at the University of Washington School of Medicine in Seattle. Dr Raychaudhuri is an assistant professor in the Clinical Research Division at Fred Hutchinson Cancer Center, as well as an assistant professor in the Division of Hematology and Oncology at the University of Washington School of Medicine. In their exclusive conversation, Drs Park, Grivas, and Raychaudhuri discussed key efficacy and safety findings from this study; the need for conducting dedicated research in bladder cancer patient populations with variant histologies; and the potential of biomarkers, such as HER2 expression, to improve the bladder cancer treatment paradigm in the future.
In this episode, Lillian Erdahl, MD, FACS, is joined by Judy Boughey, MD, FACS, from the Mayo Clinic Rochester Department of Surgery. They discuss Dr Boughey's recent article, “American College of Surgeons Cancer Programs Annual Report from 2021 Participant User File.” This inaugural annual report from the National Cancer Database describes the 2021 adult participant user files (PUF) as a whole, as well as the PUFs for breast, colon, and pancreatic cancer in more detail. It summarizes new observations and recent trends of cancer diagnoses, patient demographics, and treatment trends. Disclosure Information: Drs Erdahl has nothing to disclose. Dr Boughey receives funding paid to her institution from Eli Lilly and SymBioSis; sits on the Data Safety Monitoring Committee of CairnsSurgical; and has received honoraria from PER, PeerView, OncLive, EndoMag, and UpToDate. To earn 0.25 AMA PRA Category 1 Credits™ for this episode of the JACS Operative Word Podcast, click here to register for the course and complete the evaluation. Listeners can earn CME credit for this podcast for up to 2 years after the original air date. Learn more about the Journal of the American College of Surgeons, a monthly peer-reviewed journal publishing original contributions on all aspects of surgery, including scientific articles, collective reviews, experimental investigations, and more. #JACSOperativeWord
Welcome to The HCPFive, your go-to roundup for the latest healthcare news and breakthroughs, curated specifically for busy healthcare professionals. Each week, we highlight 5 key developments or headlines from healthcare that you need to know—whether it's a cutting-edge treatment, regulatory updates, or innovations shaping the future of medicine. This week's top stories included the US Food and Drug Administration's (FDA) acceptance of a Biologics License Application (BLA) for a cholesterol-lowering drug, long-term data on a dermatologic treatment for hidradenitis suppurativa, an expanded dosing label for a blinding eye disease treatment, and more! With The HCPFive, you'll get the essential takeaways to stay informed and ahead of the curve. Here's your quick dive into the top stories for the week of February 09, 2025—let's jump in! Interested in oncology news? Check out The OncFive, from our sister publication OncLive. Top News for Healthcare Providers from the Week of 02/09 1. FDA Accepts Lerodalcibep BLA for LDL-C Reduction in High-Risk Patients The FDA accepted the BLA for lerodalcibep, targeting reductions in low-density lipoprotein cholesterol (LDL-C) levels in patients with or at high risk for atherosclerotic cardiovascular disease (ASCVD) and primary hyperlipidemia. The agency set a Prescription Drug User Fee Act (PDUFA) action date of December 12, 2025, and announced no plans to hold an advisory committee meeting. 2. Travere Therapeutics Plans FSGS Submission for Sparsentan Travere Therapeutics announced its intent to submit a supplemental New Drug Application (sNDA) for sparsentan (Filspari) with the FDA for the treatment of focal segmental glomerulosclerosis (FSGS) at the end of Q1. The announcement arrived soon after the completion of a Type C meeting with the FDA, with the sNDA based on existing data from the Phase 3 DUPLEX and Phase 2 DUET studies. 3. Bimekizumab Long-Term Hidradenitis Suppurativa Data Support Efficacy, Safety Profile Bimekizumab (Bimzelx) was associated with sustained disease control for up to 2 years in patients with hidradenitis suppurativa (HS), according to presentation of long-term data from the BE HEARD trials. Presented at the 14th Conference of the European Hidradenitis Suppurativa Foundation (EHSF), bimekizumab reduced the symptoms of HS, achieved a low rate of flares, and improved health-related quality of life. 4. Rosnilimab Demonstrates Historic Responses for Rheumatoid Arthritis Rosnilimab achieved historic American College of Rheumatology (ACR) and clinical disease activity index (CDAI) low disease activity (LDA) responses in patients with rheumatoid arthritis (RA), according to new Phase 2b findings. A depleter and agonist of PD-1+ T cells, rosnilimab was evaluated in the global 424-patient RENOIR trial for efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with moderate-to-severe RA on background conventional disease-modifying antirheumatic drugs (cDMARDs). 5. FDA Expands Dosing Label for Avacincaptad Pegol for Geographic Atrophy The FDA approved an expanded label for avacincaptad pegol intravitreal solution (IZERVAY) for geographic atrophy (GA), extending the approved dosing beyond 12 months. Announced by Astellas Pharma, the decision comes after the company resubmitted its supplemental New Drug Application (nDA) in December 2024, based on feedback received from the FDA. The company received a Complete Response Letter (CRL) the month prior. See you next week! Editor's note: this was created with the assistance of AI tools.
In this episode of Oncology Unplugged, a podcast series from OncLive and MedNews Week, podcast host Chandler Park, MD, a medical oncologist at Norton Cancer Institute in Louisville, Kentucky, and Yan Leyfman, MD, a resident physician at Mount Sinai in New York, New York, discussed the origins and mission of MedNews Week, a global platform designed to combat health care misinformation and advance medical education. Conceived during the COVID-19 pandemic, MedNews Week was created in response to widespread misinformation and a need for accessible, evidence-based information. Over the past 2 and a half years, the platform has expanded to reach over 100 countries, focusing on underserved regions and amplifying the voices of both established oncology leaders and early-career researchers.
OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions. In today's episode, we had the pleasure of speaking with Susana M. Campos, MD, MPH, about the role of fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) in patients with HER2-positive gynecologic cancers. Dr Campos is the clinical director and the director of Educational Initiatives in the Division of Gynecologic Oncology at Dana-Farber Cancer Institute, as well as an assistant professor of medicine at Harvard Medical School in Boston, Massachusetts. In our exclusive interview, Dr Campos discussed the clinical implications of findings from the gynecologic cancer cohorts of the phase 2 DESTINY-PanTumor02 trial (NCT04482309).
Welcome to OncLive On Air®! I'm your host today, Ashling Wahner. OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions. In today's episode, we had the pleasure of speaking with Tarita Thomas, MD, PhD, MBA, and Rimas Lukas, MD, about abstracts presented during a brain cancer–focused clinical science symposium at the 2024 ASCO Annual Meeting. Dr Thomas is an associate professor of radiation oncology and Dr Lukas is an associate professor of neurology (neuro-oncology; hospital neurology) at the Northwestern University Feinberg School of Medicine in Chicago, Illinois. In our exclusive interview, Drs Thomas and Lukas discussed the results of 4 abstracts presented during the symposium. In particular, their discussion highlighted findings with ST101 in window-of-opportunity cohorts of patients with recurrent glioblastoma (GBM), the prognostic utility of cerebrospinal fluid circulating tumor DNA in recurrent high-grade glioma, the genomic drivers of GBM, and preclinical data with navtemadlin (KRT-232) in IDH wild-type GBM. ___ That's all we have for today! Thank you for listening to this episode of OncLive On Air. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field. For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters. OncLive is also on social media. On X, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn. If you liked today's episode of OncLive On Air, please consider subscribing to our podcast on Apple Podcasts, Spotify, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us! Thanks again for listening to OncLive On Air.
Welcome to OncLive On Air®! I'm your host today, Ashling Wahner. OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions. In today's episode, supported by AbbVie, we had the pleasure of speaking with Jennifer Crombie, MD, about the FDA approval of epcoritamab-bysp (Epkinly) for patients with relapsed/refractory follicular lymphoma. Dr Crombie is a physician at Dana-Farber Cancer Institute and an assistant professor of medicine at Harvard Medical School in Boston, Massachusetts. On June 26, 2024, the FDA granted accelerated approval to epcoritamab for the treatment of adult patients with relapsed/refractory follicular lymphoma who have received at least 2 prior lines of systemic therapy. This regulatory decision was supported by findings form the phase 1/2 EPCORE NHL-1 trial (NCT03625037), in which the agent yielded an overall response rate of 82% (95% CI, 74.1%-88.2%) in the primary efficacy cohort (n = 127), including a complete response rate of 60% (95% CI, 50.8%-68.4%). In our exclusive interview, Dr Crombie discussed the significance of this approval, key findings from the pivotal EPCORE NHL-1 trial, and where the future of the FL treatment paradigm is headed. ___ That's all we have for today! Thank you for listening to this episode of OncLive On Air, supported by AbbVie. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field. For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters. OncLive is also on social media. On X, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn. If you liked today's episode of OncLive On Air, please consider subscribing to our podcast on Apple Podcasts, Spotify, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us! Thanks again for listening to OncLive On Air. *OncLive On Air is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.
CancerNetwork® collaborated with OncLive® to speak with Edward S. Kim, MD, MBA, and Richard T. Lee, MD, about ongoing initiatives to expand integrative oncology for patients with cancer at City of Hope. Kim is the physician-in-chief and senior vice president at City of Hope Orange County as well as the Construction Industries Alliance City of Hope Orange County physician-in-chief chair. Lee is the Cherng Family Director's Chair of the Center for Integrative Oncology and a medical director of Supportive & Integrative Medicine in the Department of Supportive Care Medicine as well as a clinical professor of Supportive & Integrative Medicine at City of Hope. The discussion partly focused on how integrative oncology is practiced at City of Hope. The institution's style of integrative care derives inspiration from traditional Eastern medicine and encompasses modalities such as acupuncture, meditation, yoga, and massages to help treat patients with cancer more holistically. Lee cited updates in integrative therapy guidelines published by the Society for Integrative Oncology (SIO) in partnership with the American Society of Clinical Oncology (ASCO) to illustrate how integrative care can benefit patient quality of life.1 For example, he highlighted that there was strong evidence in support of implementing mindfulness-based interventions to help reduce anxiety and stress among patients. “These types of integrative therapies are a great way to complement many of the standard-of-care options that we have and provide even further benefit in controlling these symptoms and allowing patients to have a better quality of life as they go through treatment and as they head into survivorship,” Lee said. The conversation also pertained to the institution's efforts to expand the Cherng Family Center for Integrative Oncology, a first-of-its-kind national integrative oncology program, following receipt of a $100 million gift from Andrew and Peggy Cherng, co-founders and co-chief executive officers at Panda Express, supporting its creation.2 This initiative will include conducting rigorous research in a clinical program that may inform future integrative oncology guidelines, pursuing natural product drug development, and instituting educational programs that may train future integrative oncologists. "The only way we're going to be able to increase access to these important programs to more people is to do the rigorous, level 1 research that's needed in order to prove that there is a benefit of any particular area,” Kim said. “Because if we're rigorous and we show the results are positive, then we would expect them to be on the guidelines like the National Comprehensive Cancer Network, and then payers would then provide support to patients who want to have these services.” References 1. Carlson LE, Ismaila N, Addington EL, et al. Integrative oncology care of symptoms of anxiety and depression in adults with cancer: Society for Integrative Oncology–ASCO guideline. J Clin Oncol. 2023;41(28):4562-4591. doi:10.1200/JCO.23.00857 2. Logsdon Z. City of Hope receives $100 million gift to create first-of-its-kind national integrative oncology program. News release. City of Hope. September 12, 2023. Accessed March 13, 2024. https://tinyurl.com/26y3xj87
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/CHJ865. CME/MOC/AAPA credit will be available until January 5, 2025.Modern Practice Principles: A Practical “How-To” Guide for Selection, Sequencing, and Optimal Use of HER2-Targeted Therapies in HER2-Positive Breast Cancer In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, GRASP, and Living Beyond Breast Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Seagen Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerSara A. Hurvitz, MD, FACP, has a financial interest/relationship or affiliation in the form of:Grant/Research Support from Ambrx; Arvinas, Inc.; AstraZeneca; Bayer Corporation; Celcuity, Inc.; Cytomx Therapeutics, Inc.; Daiichi-Sankyo Inc.; Dantari; Dignitana AB; G1 Therapeutics, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; GlaxoSmithKline; Greenwich Life Sciences Inc; Immunomedics, Inc; Lilly; Loxo Oncology; Macrogenics, Inc.; Novartis Pharmaceuticals Corporation; OBI Pharma, Inc.; Orinove Inc.; Orum; Pfizer; Phoenix Molecular Designs; Pieris Pharmaceuticals, Inc.; Puma Biotechnology, Inc.; Radius Health, Inc.; Sanofi; Seattle Genetics, Inc./Seagen Inc.; and Zymeworks Inc.Speaker for Curio and OncLive.Stock Shareholder in RomTech, spouse.Faculty/PlannerJavier Cortes, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; AstraZeneca; Bioasis Technologies, Inc.; BioInvent International AB; Boehringer Ingelheim Pharmaceuticals, Inc.; Clovis Oncology; Daiichi Sankyo Co., Ltd; Ellipses Pharma; ExpreS2ion Biotechnologies ApS; F. Hoffmann-La Roche Ltd; GEMoaB GmbH; Gilead Sciences, Inc.; HiberCell; Jazz Pharmaceuticals, Inc.; Leuko Labs Inc.; Lilly; The Menarini Group; Merck Sharp & Dohme LLC; REVEAL GENOMICS, S.L.; Scorpion Therapeutics, Inc.; Seattle Genetics; and Zymeworks BC Inc.Grant/Research Support from ARIAD Pharmaceuticals, Inc.; AstraZeneca; Baxalta GmbH/LES LABORATOIRES SERVIER; Bayer Corporation; Eisai Inc.; F. Hoffmann-La Roche Ltd; Guardant Health; IQVIA Inc.; Merck Sharp & Dohme LLC; Pfizer; PIQUR Therapeutics; and Queen Mary University of London.Honoraria from AstraZeneca; Daiichi Sankyo Co., Ltd; Eisai Inc.; F. Hoffmann-La Roche Ltd; Gilead Sciences, Inc.; Lilly; Merck Sharp & Dohme LLC; Novartis AG; Pfizer; and Stemline Therapeutics.Faculty/PlannerPaolo Tarantino, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Daiichi Sankyo, Inc.; Gilead, and Lilly.Grant/Research Support from AstraZeneca.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/CHJ865. CME/MOC/AAPA credit will be available until January 5, 2025.Modern Practice Principles: A Practical “How-To” Guide for Selection, Sequencing, and Optimal Use of HER2-Targeted Therapies in HER2-Positive Breast Cancer In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, GRASP, and Living Beyond Breast Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Seagen Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerSara A. Hurvitz, MD, FACP, has a financial interest/relationship or affiliation in the form of:Grant/Research Support from Ambrx; Arvinas, Inc.; AstraZeneca; Bayer Corporation; Celcuity, Inc.; Cytomx Therapeutics, Inc.; Daiichi-Sankyo Inc.; Dantari; Dignitana AB; G1 Therapeutics, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; GlaxoSmithKline; Greenwich Life Sciences Inc; Immunomedics, Inc; Lilly; Loxo Oncology; Macrogenics, Inc.; Novartis Pharmaceuticals Corporation; OBI Pharma, Inc.; Orinove Inc.; Orum; Pfizer; Phoenix Molecular Designs; Pieris Pharmaceuticals, Inc.; Puma Biotechnology, Inc.; Radius Health, Inc.; Sanofi; Seattle Genetics, Inc./Seagen Inc.; and Zymeworks Inc.Speaker for Curio and OncLive.Stock Shareholder in RomTech, spouse.Faculty/PlannerJavier Cortes, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; AstraZeneca; Bioasis Technologies, Inc.; BioInvent International AB; Boehringer Ingelheim Pharmaceuticals, Inc.; Clovis Oncology; Daiichi Sankyo Co., Ltd; Ellipses Pharma; ExpreS2ion Biotechnologies ApS; F. Hoffmann-La Roche Ltd; GEMoaB GmbH; Gilead Sciences, Inc.; HiberCell; Jazz Pharmaceuticals, Inc.; Leuko Labs Inc.; Lilly; The Menarini Group; Merck Sharp & Dohme LLC; REVEAL GENOMICS, S.L.; Scorpion Therapeutics, Inc.; Seattle Genetics; and Zymeworks BC Inc.Grant/Research Support from ARIAD Pharmaceuticals, Inc.; AstraZeneca; Baxalta GmbH/LES LABORATOIRES SERVIER; Bayer Corporation; Eisai Inc.; F. Hoffmann-La Roche Ltd; Guardant Health; IQVIA Inc.; Merck Sharp & Dohme LLC; Pfizer; PIQUR Therapeutics; and Queen Mary University of London.Honoraria from AstraZeneca; Daiichi Sankyo Co., Ltd; Eisai Inc.; F. Hoffmann-La Roche Ltd; Gilead Sciences, Inc.; Lilly; Merck Sharp & Dohme LLC; Novartis AG; Pfizer; and Stemline Therapeutics.Faculty/PlannerPaolo Tarantino, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Daiichi Sankyo, Inc.; Gilead, and Lilly.Grant/Research Support from AstraZeneca.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/CHJ865. CME/MOC/AAPA credit will be available until January 5, 2025.Modern Practice Principles: A Practical “How-To” Guide for Selection, Sequencing, and Optimal Use of HER2-Targeted Therapies in HER2-Positive Breast Cancer In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, GRASP, and Living Beyond Breast Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Seagen Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerSara A. Hurvitz, MD, FACP, has a financial interest/relationship or affiliation in the form of:Grant/Research Support from Ambrx; Arvinas, Inc.; AstraZeneca; Bayer Corporation; Celcuity, Inc.; Cytomx Therapeutics, Inc.; Daiichi-Sankyo Inc.; Dantari; Dignitana AB; G1 Therapeutics, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; GlaxoSmithKline; Greenwich Life Sciences Inc; Immunomedics, Inc; Lilly; Loxo Oncology; Macrogenics, Inc.; Novartis Pharmaceuticals Corporation; OBI Pharma, Inc.; Orinove Inc.; Orum; Pfizer; Phoenix Molecular Designs; Pieris Pharmaceuticals, Inc.; Puma Biotechnology, Inc.; Radius Health, Inc.; Sanofi; Seattle Genetics, Inc./Seagen Inc.; and Zymeworks Inc.Speaker for Curio and OncLive.Stock Shareholder in RomTech, spouse.Faculty/PlannerJavier Cortes, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; AstraZeneca; Bioasis Technologies, Inc.; BioInvent International AB; Boehringer Ingelheim Pharmaceuticals, Inc.; Clovis Oncology; Daiichi Sankyo Co., Ltd; Ellipses Pharma; ExpreS2ion Biotechnologies ApS; F. Hoffmann-La Roche Ltd; GEMoaB GmbH; Gilead Sciences, Inc.; HiberCell; Jazz Pharmaceuticals, Inc.; Leuko Labs Inc.; Lilly; The Menarini Group; Merck Sharp & Dohme LLC; REVEAL GENOMICS, S.L.; Scorpion Therapeutics, Inc.; Seattle Genetics; and Zymeworks BC Inc.Grant/Research Support from ARIAD Pharmaceuticals, Inc.; AstraZeneca; Baxalta GmbH/LES LABORATOIRES SERVIER; Bayer Corporation; Eisai Inc.; F. Hoffmann-La Roche Ltd; Guardant Health; IQVIA Inc.; Merck Sharp & Dohme LLC; Pfizer; PIQUR Therapeutics; and Queen Mary University of London.Honoraria from AstraZeneca; Daiichi Sankyo Co., Ltd; Eisai Inc.; F. Hoffmann-La Roche Ltd; Gilead Sciences, Inc.; Lilly; Merck Sharp & Dohme LLC; Novartis AG; Pfizer; and Stemline Therapeutics.Faculty/PlannerPaolo Tarantino, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Daiichi Sankyo, Inc.; Gilead, and Lilly.Grant/Research Support from AstraZeneca.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/CHJ865. CME/MOC/AAPA credit will be available until January 5, 2025.Modern Practice Principles: A Practical “How-To” Guide for Selection, Sequencing, and Optimal Use of HER2-Targeted Therapies in HER2-Positive Breast Cancer In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, GRASP, and Living Beyond Breast Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Seagen Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerSara A. Hurvitz, MD, FACP, has a financial interest/relationship or affiliation in the form of:Grant/Research Support from Ambrx; Arvinas, Inc.; AstraZeneca; Bayer Corporation; Celcuity, Inc.; Cytomx Therapeutics, Inc.; Daiichi-Sankyo Inc.; Dantari; Dignitana AB; G1 Therapeutics, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; GlaxoSmithKline; Greenwich Life Sciences Inc; Immunomedics, Inc; Lilly; Loxo Oncology; Macrogenics, Inc.; Novartis Pharmaceuticals Corporation; OBI Pharma, Inc.; Orinove Inc.; Orum; Pfizer; Phoenix Molecular Designs; Pieris Pharmaceuticals, Inc.; Puma Biotechnology, Inc.; Radius Health, Inc.; Sanofi; Seattle Genetics, Inc./Seagen Inc.; and Zymeworks Inc.Speaker for Curio and OncLive.Stock Shareholder in RomTech, spouse.Faculty/PlannerJavier Cortes, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; AstraZeneca; Bioasis Technologies, Inc.; BioInvent International AB; Boehringer Ingelheim Pharmaceuticals, Inc.; Clovis Oncology; Daiichi Sankyo Co., Ltd; Ellipses Pharma; ExpreS2ion Biotechnologies ApS; F. Hoffmann-La Roche Ltd; GEMoaB GmbH; Gilead Sciences, Inc.; HiberCell; Jazz Pharmaceuticals, Inc.; Leuko Labs Inc.; Lilly; The Menarini Group; Merck Sharp & Dohme LLC; REVEAL GENOMICS, S.L.; Scorpion Therapeutics, Inc.; Seattle Genetics; and Zymeworks BC Inc.Grant/Research Support from ARIAD Pharmaceuticals, Inc.; AstraZeneca; Baxalta GmbH/LES LABORATOIRES SERVIER; Bayer Corporation; Eisai Inc.; F. Hoffmann-La Roche Ltd; Guardant Health; IQVIA Inc.; Merck Sharp & Dohme LLC; Pfizer; PIQUR Therapeutics; and Queen Mary University of London.Honoraria from AstraZeneca; Daiichi Sankyo Co., Ltd; Eisai Inc.; F. Hoffmann-La Roche Ltd; Gilead Sciences, Inc.; Lilly; Merck Sharp & Dohme LLC; Novartis AG; Pfizer; and Stemline Therapeutics.Faculty/PlannerPaolo Tarantino, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Daiichi Sankyo, Inc.; Gilead, and Lilly.Grant/Research Support from AstraZeneca.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/CHJ865. CME/MOC/AAPA credit will be available until January 5, 2025.Modern Practice Principles: A Practical “How-To” Guide for Selection, Sequencing, and Optimal Use of HER2-Targeted Therapies in HER2-Positive Breast Cancer In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, GRASP, and Living Beyond Breast Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Seagen Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerSara A. Hurvitz, MD, FACP, has a financial interest/relationship or affiliation in the form of:Grant/Research Support from Ambrx; Arvinas, Inc.; AstraZeneca; Bayer Corporation; Celcuity, Inc.; Cytomx Therapeutics, Inc.; Daiichi-Sankyo Inc.; Dantari; Dignitana AB; G1 Therapeutics, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; GlaxoSmithKline; Greenwich Life Sciences Inc; Immunomedics, Inc; Lilly; Loxo Oncology; Macrogenics, Inc.; Novartis Pharmaceuticals Corporation; OBI Pharma, Inc.; Orinove Inc.; Orum; Pfizer; Phoenix Molecular Designs; Pieris Pharmaceuticals, Inc.; Puma Biotechnology, Inc.; Radius Health, Inc.; Sanofi; Seattle Genetics, Inc./Seagen Inc.; and Zymeworks Inc.Speaker for Curio and OncLive.Stock Shareholder in RomTech, spouse.Faculty/PlannerJavier Cortes, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; AstraZeneca; Bioasis Technologies, Inc.; BioInvent International AB; Boehringer Ingelheim Pharmaceuticals, Inc.; Clovis Oncology; Daiichi Sankyo Co., Ltd; Ellipses Pharma; ExpreS2ion Biotechnologies ApS; F. Hoffmann-La Roche Ltd; GEMoaB GmbH; Gilead Sciences, Inc.; HiberCell; Jazz Pharmaceuticals, Inc.; Leuko Labs Inc.; Lilly; The Menarini Group; Merck Sharp & Dohme LLC; REVEAL GENOMICS, S.L.; Scorpion Therapeutics, Inc.; Seattle Genetics; and Zymeworks BC Inc.Grant/Research Support from ARIAD Pharmaceuticals, Inc.; AstraZeneca; Baxalta GmbH/LES LABORATOIRES SERVIER; Bayer Corporation; Eisai Inc.; F. Hoffmann-La Roche Ltd; Guardant Health; IQVIA Inc.; Merck Sharp & Dohme LLC; Pfizer; PIQUR Therapeutics; and Queen Mary University of London.Honoraria from AstraZeneca; Daiichi Sankyo Co., Ltd; Eisai Inc.; F. Hoffmann-La Roche Ltd; Gilead Sciences, Inc.; Lilly; Merck Sharp & Dohme LLC; Novartis AG; Pfizer; and Stemline Therapeutics.Faculty/PlannerPaolo Tarantino, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Daiichi Sankyo, Inc.; Gilead, and Lilly.Grant/Research Support from AstraZeneca.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/CHJ865. CME/MOC/AAPA credit will be available until January 5, 2025.Modern Practice Principles: A Practical “How-To” Guide for Selection, Sequencing, and Optimal Use of HER2-Targeted Therapies in HER2-Positive Breast Cancer In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, GRASP, and Living Beyond Breast Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Seagen Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerSara A. Hurvitz, MD, FACP, has a financial interest/relationship or affiliation in the form of:Grant/Research Support from Ambrx; Arvinas, Inc.; AstraZeneca; Bayer Corporation; Celcuity, Inc.; Cytomx Therapeutics, Inc.; Daiichi-Sankyo Inc.; Dantari; Dignitana AB; G1 Therapeutics, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; GlaxoSmithKline; Greenwich Life Sciences Inc; Immunomedics, Inc; Lilly; Loxo Oncology; Macrogenics, Inc.; Novartis Pharmaceuticals Corporation; OBI Pharma, Inc.; Orinove Inc.; Orum; Pfizer; Phoenix Molecular Designs; Pieris Pharmaceuticals, Inc.; Puma Biotechnology, Inc.; Radius Health, Inc.; Sanofi; Seattle Genetics, Inc./Seagen Inc.; and Zymeworks Inc.Speaker for Curio and OncLive.Stock Shareholder in RomTech, spouse.Faculty/PlannerJavier Cortes, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; AstraZeneca; Bioasis Technologies, Inc.; BioInvent International AB; Boehringer Ingelheim Pharmaceuticals, Inc.; Clovis Oncology; Daiichi Sankyo Co., Ltd; Ellipses Pharma; ExpreS2ion Biotechnologies ApS; F. Hoffmann-La Roche Ltd; GEMoaB GmbH; Gilead Sciences, Inc.; HiberCell; Jazz Pharmaceuticals, Inc.; Leuko Labs Inc.; Lilly; The Menarini Group; Merck Sharp & Dohme LLC; REVEAL GENOMICS, S.L.; Scorpion Therapeutics, Inc.; Seattle Genetics; and Zymeworks BC Inc.Grant/Research Support from ARIAD Pharmaceuticals, Inc.; AstraZeneca; Baxalta GmbH/LES LABORATOIRES SERVIER; Bayer Corporation; Eisai Inc.; F. Hoffmann-La Roche Ltd; Guardant Health; IQVIA Inc.; Merck Sharp & Dohme LLC; Pfizer; PIQUR Therapeutics; and Queen Mary University of London.Honoraria from AstraZeneca; Daiichi Sankyo Co., Ltd; Eisai Inc.; F. Hoffmann-La Roche Ltd; Gilead Sciences, Inc.; Lilly; Merck Sharp & Dohme LLC; Novartis AG; Pfizer; and Stemline Therapeutics.Faculty/PlannerPaolo Tarantino, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Daiichi Sankyo, Inc.; Gilead, and Lilly.Grant/Research Support from AstraZeneca.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CE/CPE/AAPA information, and to apply for credit, please visit us at PeerView.com/BUC865. CME/NCPD/CE/CPE/AAPA credit will be available until December 9, 2024.Antibody–Drug Conjugates, the Ultimate Weapons Against Solid Tumors: Latest Progress, Future Possibilities, and Implications for Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerBeth Sandy, MSN, CRNP, FAPO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc. and Janssen Pharmaceuticals, Inc.Speakers Bureau participant with Amgen Inc.; AstraZeneca; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; and Takeda Pharmaceutical Company Limited.Faculty/PlannerJamie Carroll, APRN, CNP, MSN, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Lilly; Novartis Pharmaceuticals Corporation; Pfizer; Sermonix Pharmaceuticals; and Talzenna.Speakers Bureau participant with Horizon CME and OncLive.Faculty/PlannerElizabeth Prechtel Dunphy, DNP, RN, ANP-BC, AOCN, has a financial interest/relationship or affiliation in the form of:Speakers Bureau participant with Incyte.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CE/CPE/AAPA information, and to apply for credit, please visit us at PeerView.com/BUC865. CME/NCPD/CE/CPE/AAPA credit will be available until December 9, 2024.Antibody–Drug Conjugates, the Ultimate Weapons Against Solid Tumors: Latest Progress, Future Possibilities, and Implications for Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerBeth Sandy, MSN, CRNP, FAPO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc. and Janssen Pharmaceuticals, Inc.Speakers Bureau participant with Amgen Inc.; AstraZeneca; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; and Takeda Pharmaceutical Company Limited.Faculty/PlannerJamie Carroll, APRN, CNP, MSN, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Lilly; Novartis Pharmaceuticals Corporation; Pfizer; Sermonix Pharmaceuticals; and Talzenna.Speakers Bureau participant with Horizon CME and OncLive.Faculty/PlannerElizabeth Prechtel Dunphy, DNP, RN, ANP-BC, AOCN, has a financial interest/relationship or affiliation in the form of:Speakers Bureau participant with Incyte.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CE/CPE/AAPA information, and to apply for credit, please visit us at PeerView.com/BUC865. CME/NCPD/CE/CPE/AAPA credit will be available until December 9, 2024.Antibody–Drug Conjugates, the Ultimate Weapons Against Solid Tumors: Latest Progress, Future Possibilities, and Implications for Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerBeth Sandy, MSN, CRNP, FAPO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc. and Janssen Pharmaceuticals, Inc.Speakers Bureau participant with Amgen Inc.; AstraZeneca; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; and Takeda Pharmaceutical Company Limited.Faculty/PlannerJamie Carroll, APRN, CNP, MSN, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Lilly; Novartis Pharmaceuticals Corporation; Pfizer; Sermonix Pharmaceuticals; and Talzenna.Speakers Bureau participant with Horizon CME and OncLive.Faculty/PlannerElizabeth Prechtel Dunphy, DNP, RN, ANP-BC, AOCN, has a financial interest/relationship or affiliation in the form of:Speakers Bureau participant with Incyte.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CE/CPE/AAPA information, and to apply for credit, please visit us at PeerView.com/BUC865. CME/NCPD/CE/CPE/AAPA credit will be available until December 9, 2024.Antibody–Drug Conjugates, the Ultimate Weapons Against Solid Tumors: Latest Progress, Future Possibilities, and Implications for Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerBeth Sandy, MSN, CRNP, FAPO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc. and Janssen Pharmaceuticals, Inc.Speakers Bureau participant with Amgen Inc.; AstraZeneca; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; and Takeda Pharmaceutical Company Limited.Faculty/PlannerJamie Carroll, APRN, CNP, MSN, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Lilly; Novartis Pharmaceuticals Corporation; Pfizer; Sermonix Pharmaceuticals; and Talzenna.Speakers Bureau participant with Horizon CME and OncLive.Faculty/PlannerElizabeth Prechtel Dunphy, DNP, RN, ANP-BC, AOCN, has a financial interest/relationship or affiliation in the form of:Speakers Bureau participant with Incyte.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CE/CPE/AAPA information, and to apply for credit, please visit us at PeerView.com/BUC865. CME/NCPD/CE/CPE/AAPA credit will be available until December 9, 2024.Antibody–Drug Conjugates, the Ultimate Weapons Against Solid Tumors: Latest Progress, Future Possibilities, and Implications for Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerBeth Sandy, MSN, CRNP, FAPO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc. and Janssen Pharmaceuticals, Inc.Speakers Bureau participant with Amgen Inc.; AstraZeneca; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; and Takeda Pharmaceutical Company Limited.Faculty/PlannerJamie Carroll, APRN, CNP, MSN, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Lilly; Novartis Pharmaceuticals Corporation; Pfizer; Sermonix Pharmaceuticals; and Talzenna.Speakers Bureau participant with Horizon CME and OncLive.Faculty/PlannerElizabeth Prechtel Dunphy, DNP, RN, ANP-BC, AOCN, has a financial interest/relationship or affiliation in the form of:Speakers Bureau participant with Incyte.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CE/CPE/AAPA information, and to apply for credit, please visit us at PeerView.com/BUC865. CME/NCPD/CE/CPE/AAPA credit will be available until December 9, 2024.Antibody–Drug Conjugates, the Ultimate Weapons Against Solid Tumors: Latest Progress, Future Possibilities, and Implications for Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerBeth Sandy, MSN, CRNP, FAPO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc. and Janssen Pharmaceuticals, Inc.Speakers Bureau participant with Amgen Inc.; AstraZeneca; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; and Takeda Pharmaceutical Company Limited.Faculty/PlannerJamie Carroll, APRN, CNP, MSN, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Lilly; Novartis Pharmaceuticals Corporation; Pfizer; Sermonix Pharmaceuticals; and Talzenna.Speakers Bureau participant with Horizon CME and OncLive.Faculty/PlannerElizabeth Prechtel Dunphy, DNP, RN, ANP-BC, AOCN, has a financial interest/relationship or affiliation in the form of:Speakers Bureau participant with Incyte.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CE/CPE/AAPA information, and to apply for credit, please visit us at PeerView.com/BUC865. CME/NCPD/CE/CPE/AAPA credit will be available until December 9, 2024.Antibody–Drug Conjugates, the Ultimate Weapons Against Solid Tumors: Latest Progress, Future Possibilities, and Implications for Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerBeth Sandy, MSN, CRNP, FAPO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc. and Janssen Pharmaceuticals, Inc.Speakers Bureau participant with Amgen Inc.; AstraZeneca; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; and Takeda Pharmaceutical Company Limited.Faculty/PlannerJamie Carroll, APRN, CNP, MSN, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Lilly; Novartis Pharmaceuticals Corporation; Pfizer; Sermonix Pharmaceuticals; and Talzenna.Speakers Bureau participant with Horizon CME and OncLive.Faculty/PlannerElizabeth Prechtel Dunphy, DNP, RN, ANP-BC, AOCN, has a financial interest/relationship or affiliation in the form of:Speakers Bureau participant with Incyte.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CE/CPE/AAPA information, and to apply for credit, please visit us at PeerView.com/BUC865. CME/NCPD/CE/CPE/AAPA credit will be available until December 9, 2024.Antibody–Drug Conjugates, the Ultimate Weapons Against Solid Tumors: Latest Progress, Future Possibilities, and Implications for Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerBeth Sandy, MSN, CRNP, FAPO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc. and Janssen Pharmaceuticals, Inc.Speakers Bureau participant with Amgen Inc.; AstraZeneca; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; and Takeda Pharmaceutical Company Limited.Faculty/PlannerJamie Carroll, APRN, CNP, MSN, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Lilly; Novartis Pharmaceuticals Corporation; Pfizer; Sermonix Pharmaceuticals; and Talzenna.Speakers Bureau participant with Horizon CME and OncLive.Faculty/PlannerElizabeth Prechtel Dunphy, DNP, RN, ANP-BC, AOCN, has a financial interest/relationship or affiliation in the form of:Speakers Bureau participant with Incyte.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CE/CPE/AAPA information, and to apply for credit, please visit us at PeerView.com/BUC865. CME/NCPD/CE/CPE/AAPA credit will be available until December 9, 2024.Antibody–Drug Conjugates, the Ultimate Weapons Against Solid Tumors: Latest Progress, Future Possibilities, and Implications for Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerBeth Sandy, MSN, CRNP, FAPO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc. and Janssen Pharmaceuticals, Inc.Speakers Bureau participant with Amgen Inc.; AstraZeneca; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; and Takeda Pharmaceutical Company Limited.Faculty/PlannerJamie Carroll, APRN, CNP, MSN, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Lilly; Novartis Pharmaceuticals Corporation; Pfizer; Sermonix Pharmaceuticals; and Talzenna.Speakers Bureau participant with Horizon CME and OncLive.Faculty/PlannerElizabeth Prechtel Dunphy, DNP, RN, ANP-BC, AOCN, has a financial interest/relationship or affiliation in the form of:Speakers Bureau participant with Incyte.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CE/CPE/AAPA information, and to apply for credit, please visit us at PeerView.com/BUC865. CME/NCPD/CE/CPE/AAPA credit will be available until December 9, 2024.Antibody–Drug Conjugates, the Ultimate Weapons Against Solid Tumors: Latest Progress, Future Possibilities, and Implications for Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerBeth Sandy, MSN, CRNP, FAPO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc. and Janssen Pharmaceuticals, Inc.Speakers Bureau participant with Amgen Inc.; AstraZeneca; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; and Takeda Pharmaceutical Company Limited.Faculty/PlannerJamie Carroll, APRN, CNP, MSN, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Lilly; Novartis Pharmaceuticals Corporation; Pfizer; Sermonix Pharmaceuticals; and Talzenna.Speakers Bureau participant with Horizon CME and OncLive.Faculty/PlannerElizabeth Prechtel Dunphy, DNP, RN, ANP-BC, AOCN, has a financial interest/relationship or affiliation in the form of:Speakers Bureau participant with Incyte.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
JCO PO author Alexander E. Drilon, MD, shares insights into his article, “Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase Fusion–Positive Lung Cancers” and the article's findings of the activity of larotrectinib in patients with advanced lung cancer harboring NTRK gene fusions. Host Dr. Rafeh Naqash and Dr. Drilon discuss drug development, testing for fusions, resistance mechanisms, and cancer metastases. Click here to read the article! TRANSCRIPT Dr. Rafeh Naqash: Hello and welcome to JCO Precision Oncology Conversations, where we bring you engaging conversations with authors of clinically relevant and highly significant JCO PO articles. I am your host, Dr. Rafeh Naqash, Social Media Editor for JCO Precision Oncology, and Assistant Professor at the OU Stephenson Cancer Center. Today we are excited to be joined by Dr. Alexander Drilon, Chief of the Early Drug Development Service and Medical Oncologist on the Thoracic Oncology Service at the Memorial Sloan Kettering Cancer Center and lead author of the JCO Precision Oncology article “Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase Fusion–Positive Lung Cancers.” Our guests' disclosures will be linked in the transcript. Dr. Drilon, welcome to the podcast and thank you for joining us today. We're really excited to be discussing this topic with you. Dr. Alexander Drilon: It's my pleasure and thank you for the invitation. Dr. Rafeh Naqash: For the sake of this podcast, we will refer to each other using our first names. So, Alex, you've led the development for some of these agents targeting NTRK. So it's really timely that you're coming onto this podcast to not just discuss this very interesting paper that you published in JCO Precision Oncology, but also the general landscape of NTRK. So could you briefly tell us about the history of the drug development process behind NTRK fusions, when it started, how you got involved, and where it stands currently? Dr. Alexander Drilon: Sure. So, as you mentioned, my background is in lung cancer, where when I came on as a fellow, there was a lot of excitement around EGFR and ALK, but then subsequently other oncogene drivers were also discovered and many of them were fusion. So, as we know, ALK in the fuse state is a driver of many tumors, as is ROS1 and RET. And interestingly, NTRK fusions share many similarities with ALK, RET, and ROS1 in that you have an intact kinase domain that's in the three prime position, it's fused to a different gene in the five prime position and basically describes oncogenesis. And the beautiful thing about NTRK fusions is that they are widely found across many different cancers. And I like to think of these cancers in two major buckets. So there is a bucket for cancers that are rare where we see these NTRK fusions with a very high frequency. And examples here are your secretory carcinomas of the salivary gland and the breast, for example, more congenital fibrosarcoma, where the frequency exceeds 90% in some series, and then there are much more common tumors where the frequency is much lower. So lung cancer is an example where you find it in less than 1% of cases. There are some other tumors like GI cancers also where the frequency is low. And beyond these two major groups, we also see these NTRK fusion-positive cancers occur not just in the adult population, but the pediatric population. All of that thrown together means that it was a really great setup for exploring the activity and safety of targeted therapy in what we call a ‘basket trial' paradigm, where you design a trial and instead of selecting patients based on cancer type, you ignore cancer type and, of course, you accrue by an enrolling alteration, which in this case is the NTRK fusion. Dr. Rafeh Naqash: Excellent. Thank you for that summary. It's interesting that just yesterday in my phase I clinic, I had an individual who was supposed to go on a certain study, and liquid biopsy came back and showed an NTRK fusion for a very odd presentation of a prostate cancer, which, again, got me thinking about the paper that you published trying to read about NTRK and then this happened and I got thinking about a bunch of other questions. But, for starters, though, from a receptor standpoint and I know you published on this in different journals, could you briefly tell, for the sake of the audience, describe the pathway and the tyrosine kinase signaling and associated resistance pathways that are concurrently acting in a different direction, perhaps, and also discuss briefly from neural development? I know the pathway, the NTRK gene or TRK gene as such is involved in different neuronal signaling aspects. Could you briefly touch on that? Dr. Alexander Drilon: Sure. And thankfully there are a lot of parallels with other things that perhaps some of the listeners are more familiar with. We'll start with the fact that it is a receptor tyrosine kinase, NTRK. It's a gene that encodes a receptor tyrosine kinase just like other receptor tyrosine kinases that may be fused such as ALK, RET, and ROS1. But remember also that other RTKs are EGFR, FGFR, which are also well known. The important thing to remember for NTRK is that you have three different genes, NTRK 1, 2, and 3 that encode three different proteins which are called TRK A, B, and C. And as you intimated, in the non-oncogenic state, these are very important for the development and the maintenance of the nervous system. And in the fused state, of course, similar to other fusions that we spoke about, the chimeric oncoprotein will drive downstream signaling and tumor growth and metastases. And in general, these cancers can be very reliant on downstream signaling in the MAP Kinase pathway but may also on occasion activate other downstream pathways like the PI3 Kinase pathway. Dr. Rafeh Naqash: And I know some of that could potentially play into resistance mechanisms for some of these first or second-generation NTRK inhibitors. From a fusion partner standpoint, the data that I came across that you're very well aware of is different fusion partners, and maybe some have a slightly better prognosis than some other fusions. But, in your practice and in your experience, does it matter what the other fusion partner is if the kinase domain is intact, meaning the signaling for the NTRK gene is intact? Have you seen any differences there from the other fusion partner standpoint? Dr. Alexander Drilon: From a patient-matching perspective, as long as you think the fusion is real, and by that I mean that you look at the report and you're sure the kinase domain is there and you're sure it's in frame, meaning connected well to the five prime partner so that the DNA strand is read through, the five prime partner does not play a major role in my deciding to give a TRK inhibitor or not. I would give anyone with a functional NTRK 1, 2, or 3 fusion a TRK inhibitor. Now, the data on whether or not select fusions do better than others is, I would say, still a little immature and perhaps conditioned by a few things. There are some of the cancers in the first bucket that we talked about, like the secretory carcinomas that harbor a recurrent event such as ETV6 NTRK3. And those cancers, in my experience in clinic, patients with those tumors can be on a TRK inhibitor for a very long time. And it's unclear if that's because of the exact fusion event or if it's because of the cancer type that might be more, say, genomically naïve compared to a gastrointestinal tumor, like a colorectal cancer with an NTRK fusion. So I hesitate to say that there are very strong and convincing data that if you have a particular five prime partner, you'll absolutely do better or worse. So, in the interim, I think the most important piece is just making sure that the event is real and actionable, and if it is, then you can give a TRK inhibitor. Dr. Rafeh Naqash: Thank you so much. I totally agree. And I think, for the sake of our listeners, as we see more and more sequencing being done on patients with cancer in the advanced stage setting especially, it's important to keep in mind when you have something that you can act on that has an actionable target that is FDA approved, then it's important to give the patient that option, especially in rare fusion events such as NTRK or TRK. Now, you've touched upon this in your paper, but before we go into the details of the paper, specifically, I wanted you to briefly talk about the testing mechanisms which are important for some of these fusions and play into, for example, ROS1 ALK fusions also. Could you tell us what are the most appropriate ways to test for these fusions in patients harboring cancers, both from a tissue standpoint and from a blood-based assay standpoint? Dr. Alexander Drilon: This is a great question because if you don't have a test that's optimally poised to pick up an NTRK fusion, then you can't act on it. And a patient who would have benefited very durably from a TRK inhibitor won't get access to it. So there are different ways of testing for NTRK fusions, and I like to think of the central dogma here where you have DNA becomes RNA becomes protein because that really helps anchor the different types of assays that you might use. We commonly use next-generation sequencing of DNA, but even if you have a very good next-generation sequencing assay, that does have its limitations because there are some fusions that are structurally just difficult to pick up even with a great DNA-based NGS assay. And for that reason, we and others have found that in tumors that have an equivocal NTRK fusion, or perhaps where you didn't find something but you really suspect that you missed something, particularly in cases where, historically, like congenital fibrosarcoma where you know there's a very good likelihood of finding NTRK fusion, we then reach for an RNA-based assay because at the RNA level, you've removed things like the intra-DNA based capture challenging. And so I think that from a nucleic acid standpoint, leveraging a test that looks both at DNA and RNA, maximizes the likelihood of finding this fusion. And just remember that there are different NGS assays in terms of the approach to design and some might be more Amplicon-based and that's less optimal, but the hybrid-capture-based ones tend to be better. The DNA and RNA tests can be done on tumors, and in blood, you could do a liquid biopsy. It's very hard to fish out RNA in blood given the current technology so we're still limited to circulating tumor DNA which shares the liabilities of doing DNA testing on a tumor sample. But if you find it and it looks real, then it's certainly actionable even if you detect an NTRK fusion with a liquid biopsy. Now going back to the central dogma there, the third piece which we haven't touched on is protein. And there have been many papers published now on the utility of immunohistochemistry, and this helps you confirm that the TRK A, B, and C proteins are actually expressed. And what tends to happen is in many fusions, the chimeric oncoproteins strongly express as TRK A, B, and C that helps provide a complementary test or assay that confirms that you're dealing with something that is actionable. So that is a very contemporary approach and a very thorough approach to looking for these NTRK fusions where you do DNA and RNA if possible. And if you still have questions, ask your pathologist to see if they can do Pan-TRK IHC. But depending on the resource environment that you're in, there are older tests like FISH which we use for ALK that can also find these fusions. RT-PCR which only finds particular events, these can detect NTRK fusions but really don't have the breadth and comprehensiveness as the other assays that we discussed like NGS. Dr. Rafeh Naqash: Thank you so much, Alex, for that amazing summary of all the methods that potentially could help detect this rare but important event. From a therapeutic standpoint, now, taking a deeper dive into your very interesting JCO Precision Oncology paper that looked at larotrectinib data from a pooled analysis of two trials, a phase II and a phase I. Could you tell us a little background about these two trials, the patient population and what kind of data were you trying to evaluate? And then we can discuss some of the interesting results that you showcase in the paper. Dr. Alexander Drilon: It really helps as a background to realize that the initial approach to this was really on a basket trial where the programs for larotrectinib, which is a selective TRK A, B, and C inhibitor, and the other drug entrectinib, which inhibits ROS1 in addition to TRK, really accrued pediatric and adult cancers with NTRK fusions. And this paper pulls out the lung cancer subset and we'll discuss that in detail. But before getting into that, it's important to know that in the tumor agnostic data set of all patients with an NTRK fusion of any type, larotrectinib achieved a response rate of approximately 80%, entrectinib of approaching 60%, and disease control was durable with a median PFS for larotrectinib of approximately 28 months, and with entrectinib numerically, the number was lower at 11 months. So with that background, this paper in JCO PO, in the interest of featuring the activity for lung cancers with NTRK fusions, pulled out 20 patients with NTRK fusion-positive lung cancers. And the punchline is that the activity was pretty comparable to that seen with a bigger data set. So the objective response rate was 73% and many patients had a partial response, 67% of the cases, 7% had a complete response, and really only a minority had primary progressive disease, 1 patient out of the 15 evaluable patients. These responses and clinical benefit overall were durable and the median duration of response was almost 34 months, with a median progression-free survival of almost 35 and a half months and an overall survival median of 40.7 months. And just to talk about how that stacks up compared to other targeted therapies, this certainly is in the ballpark of some of the best ALK inhibitors that we have for ALK fusion-positive lung cancer. It's also comparable to osimertinib for EGFR mutant lung cancer. So we can confidently view TRK inhibition in lung cancers with NTRK fusions as a highly-active therapy. Dr. Rafeh Naqash: Absolutely. I think you touched upon this earlier where in your cohort at least 50% of patients had central nervous system involvement, and it looks like larotrectinib does have CNS activity and benefit. Could you speak to the differences between potential entrectinib and larotrectinib from a CNS efficacy standpoint? And the second part of that question was going to be when you identify this fusion in patients, for example, with lung cancer, now, since TRK does have a role in neuronal development, do you think there is a role for closer CNS monitoring in these patients if they have not had brain metastasis identified because of the fact that they have an NTRK fusion? Is there some predilection for CNS involvement from a metastasis standpoint? It's just something that I've been thinking of over the last couple of days after I saw my patient who does have CNS involvement but with prostate cancer, which I have not seen in the phase I setting in all the prostate patients that I've come across. So what are your thoughts on that? Dr. Alexander Drilon: These are great questions. In lung cancers with NTRK fusions, there is a proclivity for metastasis to the CNS. And thankfully, both of these TKIs, larotrectinib and entrectinib, do have coverage of the CNS. Now, from a design perspective, the initial thought was perhaps entrechtinib was more CNS-penetrant. But if you look at the overall response rates in patients with brain metastases and the intracranial response rates where you have patients with target lesions in the brain that you're able to measure; if you look across the aisle, entrectinib and larotrectinib have comparable results, with the objective response rate being in the order of 50% to 60% and the intracranial response rate being also in the order of about 50% to 60%. So at the end of the day, it appears as if, despite the previous hypothesis that maybe one drug would work better in the CNS than the other, we're seeing equally good effects with both drugs. For the second question you asked, it's also a very interesting question because, like you mentioned, the TRK receptors play a role in nervous system development. But we have not observed a much higher frequency of CNS metastases in NTRK fusion-positive lung cancers or cancers in general that I know of, compared to cancers that are wild type for an oncogene or have other oncogenes. So what's more important really to think about when you sort of chew on the fact that these TRK inhibitors are involved in nervous system development are the potential side effects that you may see in patients that you treat with these TRK inhibitors. Dr. Rafeh Naqash: Absolutely. Now, from the therapy standpoint that you discuss here, duration of responses, objective responses that you saw in your analysis were very impressive for these patients with lung cancer. In your clinical practice if you see a lung cancer patient with this fusion and you treat them with larotrectinib or entrectinib, and they have, let's say, de novo CNS metastases that are asymptomatic, do you generally try the targeted therapy first and hold off, perhaps, brain directed therapy in that setting? Similar to what one would do with osimertinib perhaps or alectinib? Dr. Alexander Drilon: Absolutely. It's the same paradigm because we know that we are seeing in a larger population of patients, just generally good activity, both extracranially and intracranially. The goal is to try to spare patients the extra side effects of doing radiation by only giving the TKI. And in practice, even outside of the trial, in patients that I've treated with CNS metastases, the activity has been very good. Dr. Rafeh Naqash: Thank you so much. Now, all TKI therapies have, unfortunately, resistance mechanisms that come up eventually, in my experience at least. What is your experience as far as understanding resistance mechanisms on TRK-based therapies and potential second options after that, whether it's second-generation TRK inhibitors or subsequent targeted therapies in this space? Dr. Alexander Drilon: Thankfully, this has been looked at extensively and I like to categorize resistance into two major groups. So there's a type of resistance which we call on-target resistance and another type which we call off-target resistance. In simple terms, cancers that acquire on-target resistance are still dependent on the NTRK or TRK pathway. And often what happens is, like with other oncogene-targeted therapy pairs, you see the acquisition of a resistance mutation in the kinase domain of NTRK 1, 2, 3 that either changes the dynamics of the kinase or sort of kicks the drug off of the binding site due to steric hindrance. And for those patients, companies have designed next-generation TRK inhibitors that abrogate resistance, meaning they were designed so that they would work despite the presence of these resistance mutations. And a few of them include repotrectinib, talatrectinib, and selitrectinib that are thought to have activity, but there are many other newer ones that are currently being explored. I will say that there's proof of concept that has been published as well showing that patients who progress on a first-generation TRK inhibitor like larotrectinib or entrectinib who develop acquired resistance that's on-target can respond very well to a next-generation NTRK inhibitor. And while these aren't approved just yet, these are of course available in clinical trials. Now, the second major group is more problematic. This is off-target resistance. And when I describe this to patients, what I usually say is that the cancer sort of ‘phones a friend' and activates a second gene perhaps that isn't NTRK. And examples of that include KRAS or MET or BRAF, very well-known oncogenes in other contexts, but it leads to a reliance outside of the NTRK or TRK pathway per se, which still effectively reactivates the MAP kinase pathway. What to do in that situation? Well, there are select cases and there have been case reports published of patients who get a combination. Say if it's acquired MET amplification, you give a MET inhibitor with a TRK inhibitor and that combination can work. But in many other cases where you don't have access to a combination on a clinical trial or on compassionate use, then you really default to the standard of care for that cancer type. So if it's lung cancer and they've never had chemotherapy before, then it would be platinum-based chemotherapy, say with pemetrexed and a third drug, perhaps if they have lung adenocarcinoma. Dr. Rafeh Naqash: Thank you so much. This is definitely an exciting field and exciting time to be in this space of drug development, and especially when we have so many interesting tumor-agnostic approvals that have come along in the last few years and more to come. And you've led a lot of this development with several other leaders in this field. So it was very nice discussing this with you, and hopefully, our listeners find it equally interesting and educationally relevant to what we see day in and day out as we perform more and more sequencing for patients with cancer and try to identify some of these rare or not so rare events that are targetable and can definitely change the course of a patient's therapy and outcomes. So thank you once again, Alex, for the discussion on this paper. But before we end, we'd like to spend a couple of minutes trying to know about the investigator. So could you tell us a little bit about your career trajectory, how you started your fellowship perhaps, how you ended up in drug development, and how you've successfully contributed so much in this field to date? Dr. Alexander Drilon: Sure. So I'm originally from the Philippines, was born there, finished med school, and really wanted to come to the United States to sort of broaden my education and my residency program in internal medicine, then called St. Luke's Roosevelt under Columbia, had a program that sent people to rotate through Memorial Sloan Kettering Cancer where I currently work. So that was my first exposure with oncology. I fell in love with it and eventually became a fellow, fortunately, at Memorial Sloan Kettering. And I mentioned earlier that during that time I had subspecialized in lung cancer and there was a lot of excitement around targeted therapy for oncogene-driven lung cancer. And that was my point of entry. I saw these drugs work very well and I said that if I were in a position to develop newer agents, perhaps for other oncogenes where there wasn't anything developed just yet, that would be really cool. And that was my entry into the phase I world where things later on expanded really the tumor agnostic interrogation using the same principles that were familiar to me in the lung cancer world. And I think I've been very fortunate with the environment and the ability, especially with good in-house sequencing, to match many patients to these trials. And it's been wonderful to see several of these drugs approved. Larotrectinib was the sort of seminal tumor-agnostic approval of a targeted therapy for the first time by any regulatory body. And like you said, the hope is that we see several more of these. Dr. Rafeh Naqash: Awesome. That sounds like a very interesting, phenomenal journey that you've had, and a lot of it is also probably related to the kind of people that you met, mentors, and other people who helped you along the way. And then, of course, you've done a lot for other fellows and trainees in this space of drug development. So thank you again, Alex, for joining us, and thank you for choosing JCO Precision Oncology as a destination for your work. I look forward to interacting with you further subsequently and hopefully seeing more development in this space of novel therapies for fusions and other interesting targets in the lung cancer space. So thank you for listening to JCO Precision Oncology Conversations. Don't forget to give us a rating or review and be sure to subscribe so you never miss an episode. You can find all ASCO shows at asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Bio: Alexander E. Drilon, MD, is a medical oncologist specializing in the treatment of lung cancer. He is chief of early drug development service at Memorial Sloan Kettering Cancer Center. He has clinical expertise in lung cancer and early-phase clinical trials. COIs Alexander Drilon Honoraria: Medscape, OncLive, PeerVoice, Physicians' Education Resource, Targeted Oncology, MORE Health, Research to Practice, Foundation Medicine, PeerView Consulting or Advisory Role: Ignyta, Loxo, TP Therapeutics, AstraZeneca, Pfizer, Blueprint Medicines, Genentech/Roche, Helsinn Therapeutics, BeiGene, Hengrui Therapeutics, Exelixis, Bayer, Tyra Biosciences, Verastem, Takeda/Millennium, BerGenBio, MORE Health, Lilly, AbbVie, 14ner Oncology/Elevation Oncology, Remedica, Archer, Monopteros Therapeutics, Novartis, EMD Serono/Merck, Melendi, Repare Therapeutics Research Funding: Foundation Medicine Patents, Royalties, Other Intellectual Property: Wolters Kluwer (Royalties for Pocket Oncology) Other Relationship: Merck, GlaxoSmithKline, Teva, Taiho Pharmaceutical, Pfizer, PharmaMar, Puma Biotechnology
About Our Guest Dr. Pei-Chun McGregor, MD, FACC (she/her) is currently the Director of Ambulatory Cardiology and Stress Laboratory at the Veterans Affairs Boston Healthcare System, an instructor of medicine at Harvard Medical School, and a Lieutenant Colonel in the US Air Force Reserves. She is a board-certified general cardiologist with a focus on adult echocardiography, nuclear cardiology, and vascular imaging. Dr. McGregor is a graduate of New York University School of Medicine. As a recipient of the Health Professions Scholarship, she went on to complete her internal medicine residency and cardiovascular fellowship at San Antonio Uniformed Services Health Consortium. She served in the United States Air Force for over 11 years and continues her service as a Lieutenant Colonel in the Air Force Reserves to date. Throughout her academic career, Dr. McGregor has demonstrated dedication to medical education as a regular lecturer to trainees and has had a significant contribution to the literature on topics in echocardiography. She has also been featured online by both OncLive and PracticeUpdate. She is an active member of the American College of Cardiology, American Society of Echocardiography, American Registry of Diagnostic Medical Sonography and Society of Vascular Ultrasound. Recently, she was chosen to be part of the first ever I.D.E.A. Group at Inteleos.
Michael Sapienza, Chief Executive Officer of the Colorectal Cancer Alliance, lost his mother to colorectal cancer in May 2009. He turned his profound grief into action, inspiring and challenging the colorectal cancer community, family, friends, and professional associates to follow his lead and dedicate themselves to ending colorectal cancer within our lifetime—the mission of the Colorectal Cancer Alliance. Michael founded The Chris4Life Colon Cancer Foundation and served as its President from 2010-2015. In 2016, he led the team that merged the Foundation and the Colon Cancer Alliance, creating the nation's largest colon cancer specific nonprofit, which changed its name to Colorectal Cancer Alliance in 2017 to embrace both the colon and rectal cancer communities. Over the last decade, Michael has become an expert and trusted voice on the topics of colorectal cancer prevention, patient care, and medical research. Michael regularly appears on TV and radio programs throughout the United States, including NBC's TODAY show. He is frequently quoted in national publications such as USA Today, Newsweek, and The New York Times, promoting awareness and the importance of increased funding for colorectal cancer research and early detection. Michael is a member of The Ruesch Center for the Cure of GI Cancer's Advisory Board at Georgetown University, and in 2020 he was appointed to the President's Cancer Panel and NCCRT's 2021 Steering Committee. In 2014, Michael received three prestigious industry awards: David Jagelman, MD Award for advocacy in Colorectal Cancer Awareness by the American Society of Colon and Rectal Surgeons; the Public Service Award from the Society for Surgery of the Alimentary Tract; and the Champion Award from Preventing Colorectal Cancer. In 2018, Michael was honored with a Luminary Award from OncLive and The Ruesch Center for his lifetime commitment to improving the lives of patients affected by gastrointestinal cancer. Michael holds degrees from both Northwestern University and Rice University and currently resides in the District of Columbia.
For one cancer center, an outgrowth of the COVID-19 pandemic spurred plans to create an urgent care center for patients with cancer so that they could stay out of the emergency department. The Winship Cancer Institute of Emory University began planning for construction in 2020 after receiving a sizeable donation and broke ground this year. The Rollins Immediate Care Center is expected to open in 2022. On this episode of Managed Care Cast, we bring you an interview conducted by the editorial director of OncLive®, Gina Mauro, who talks with Charise Gleason, MSN, NP-BC, AOCNP, the advance practice provider chief at Winship Cancer Institute, about how having a dedicated cancer urgent care center will make cancer treatment plans seamless while also helping patients avoid exposure to infectious diseases in emergency waiting rooms.
Returning guest, Dr. Neal Shore, MD, FACS, Medical Director for the Carolina Urologic Research Center discusses the importance of patient-centric treatment decision-making and the publication of an easy-to-understand summary of important clinical trial data in "Future Oncology", a leading medical journal (Online Feb 2021). Neal D. Shore, MD, FACS, is the Medical Director for the Carolina Urologic Research Center. He practices with Atlantic Urology Clinics in Myrtle Beach, South Carolina. Dr. Shore has conducted more than 350 clinical trials, focusing mainly on genitourinary oncology, and serves on the executive boards of the Society of Urologic Oncology and the Bladder Cancer Advocacy Network. He is Past President of the Large Urology Group Practice Association. He is a founder for both CUSP Clinical Trials Consortium and DASHKO, a national urology practice data registry. He serves as the National Urology Research Director for 21st Century Oncology. He has served on the AUA Male Health Committee and the AUA Data Committee, the SITC Task Force for Prostate Cancer, the Bladder Cancer Advocacy Think Tank, and the Editorial Boards of Review in Urology, Urology Times, Chemotherapy Advisor, OncLive, PLOS ONE, Urology Practice, and World Journal of Urology. He serves as Editor of Everyday Urology-Oncology. Dr. Shore has written more than 200 peer-reviewed publications and numerous book chapters. He performs peer review for Lancet Oncology, New England Journal of Medicine, European Urology, the Journal of Urology, Urology, BJUI, PCPD, and numerous other high-impact scientific journals. A graduate of Duke University and Duke University Medical School, Dr. Shore completed a 6-month clinical research fellowship in Pretoria, South Africa, and then completed his General Surgery/Urology training at New York Hospital Cornell Medical Center and at Memorial Sloan-Kettering Cancer Center in New York City. He is a Fellow of the American College of Surgeons. #FutureOncology
© 2020-2025 Ivy Podcast Discovery LLC
